Abstract 3198: TK-6302, a supercharged PRAME TCR-T cell therapy containing a high affinity TCR, an activating CD8 coreceptor (costimCD8 CoR) and a Fas-based switch receptor, drives sustained anti-tumor responses
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-3198
Abstract: T cell receptor (TCR) T cell therapy targeting PRAME mediates durable responses in melanoma and sarcoma but has shown limited efficacy in other solid tumors. Suboptimal T cell engraftment and fitness and immune suppression by… read more here.
Keywords: prame; supercharged prame; tcr; cell ... See more keywords